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ABSTRACT: Phenylazopyridines are photoisomerizable com-
pounds with high potential to control biological functions with
light. We have obtained a series of phenylazopyridines with light
dependent activity as negative allosteric modulators (NAM) of
metabotropic glutamate receptor subtype 5 (mGlu5). Here we
describe the factors needed to achieve an operational molecular
photoisomerization and its eﬀective translation into in vitro and in
vivo receptor photoswitching, which includes zebraﬁsh larva
motility and the regulation of the antinociceptive eﬀects in mice.
The combination of light and some speciﬁc phenylazopyridine ligands displays atypical pharmacological proﬁles, including light-
dependent receptor overactivation, which can be observed both in vitro and in vivo. Remarkably, the localized administration of
light and a photoswitchable compound in the peripheral tissues of rodents or in the brain amygdalae results in an illumination-
dependent analgesic eﬀect. The results reveal a robust translation of the phenylazopyridine photoisomerization to a precise
photoregulation of biological activity.
■ INTRODUCTION
The therapeutic use of chemical compounds has historically
driven medicine to exceptional achievements in the prevention
and treatment of diseases.1 Drug discovery is now a
multidisciplinary activity in permanent motion to achieve new
therapeutic challenges for unmet clinical needs. However, in
spite of increasing R&D eﬀorts, continuous technical progress,
and outstanding scientiﬁc achievements, new drugs are scarce.2
Although the reasons for this are multiple, drug discovery is
facing problems associated with the increasing complexity of
diseases and therapeutic targets, which require more precise
therapeutics and can be connected to the lack of eﬀective and
truly innovative medicines.3 Conventional pharmacology
involves drug interaction with a target protein and the
induction of changes in its functional activity to trigger the
therapeutic response. However, in practice after the drug is
systemically administered to an organism, the precise control of
its action at the target protein is lost.4 Photopharmacology may
provide solutions to this problem since it enables the
spatiotemporal control of target proteins with light-regulated
receptor-speciﬁc drugs.5,6 In particular, light can restrain the
drug action site and enable accurate dosing patterns5 that can
be adjusted in real-time mode.
Photopharmacological strategies have proven successful in
the regulation of free ligands of ion channels4,6 and inhibitors of
protein−protein interactions7 but in many cases require genetic
modiﬁcation of the target receptor.8 Genetic manipulation can
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be circumvented by drug azologization,9−11 which is based on
the insertion of azobenzene units into the chemical scaﬀold of
existing ligands to obtain new photoswitchable molecules but
maintaining the drug-like properties of the original ligand.9,10
Some successful examples are bis-Q,12 gluazo,13 azo-propo-
fols,14 AzoTHA,15 fotocaine,9 JB253,16 and PST-1.17
Recently, we reported on alloswitch-1 (1a)11 (Figure 1A), a
phenylazopyridine derivative as the ﬁrst GPCR photoswitchable
allosteric modulator with activity in vivo.
Instead of the classical photoisomerizable azobenzene, we
used a structurally related phenylazopyridine, which includes
several potential advantages such as a better solubility and a
faster thermal decay of the cis to the trans isomer enabling a
potentially better spatiotemporal control of the activity of the
compound. There are some drugs containing a phenyl-
azopyridine scaﬀold, with diﬀerent biological activities,18−24
but they have not been described or exploited as photo-
switchable entities or light-dependent drugs. In contrast,
alloswitch-1 selectively exhibited a potent negative allosteric
modulation (NAM) activity of mGlu5 receptor, which belongs
to the metabotropic glutamate (mGlu) GPCR family and
controls important neuronal and glial functions.25 Indeed, the
trans isomer of alloswitch-1 inhibited mGlu5 agonist response at
nanomolar concentrations, whereas it was inactive in the cis
conﬁguration. Another phenylazopyridine (SIB-1757)26 was
previously reported as an mGlu5 NAM with an IC50 in the
nanomolar range, but its photoswitching properties were never
studied. Two other potent mGlu5 NAMs, MPEP and XGS-RC-
009, maintain a high structural resemblance to SIB-1757 and
alloswitch-1, but they include a phenylethynylpyridine moiety
instead of the phenylazopyridine27 (Chart 1), maintaining
similar mGlu5 NAM activity. Taking advantage from this
structural parallelism and as many potent mGlu5 NAMs
preserve the 2-arylethynylpyridine structure, such as MPEP,
GRN-529, STX107, and Raseglurant28 (Chart 1), we designed
a family of potent mGlu5 NAMs based on the 2-phenyl-
azopyridine scaﬀold. With these compounds we intended to
determine the molecular and photochemical features that
deﬁne an eﬃcient photoreversible ligand for operating in cells
and living animals. We also investigated whether these
molecules can be used to eﬀectively control temporal dosing
patterns with light in biological systems.
Interestingly, while exploring the photoswitching properties
of these phenylazopyridines, we found that some compounds
induced an overactivation of the receptor activity in vitro and
increased animal motility in vivo. We also report on these light-
dependent atypical pharmacological proﬁles.
Figure 1. Design of the phenylazopyridine series. (A) Alloswitch-1 is a
photoswitchable allosteric inverse agonist of mGlu5, in its trans
conﬁguration. (B) We designed and synthesized 20 photoswitchable
derivatives of alloswitch-1, with the same phenylazopyridine scaﬀold.
With violet light (380 nm) they switch from the thermodynamically
stable trans isomer to the cis isomer and switch back to the trans
isomer with green light (500 nm) or thermally, without illumination.
Chart 1. mGlu5 NAMs with 2-Arylethynylpyridine, SIB-1757, and Fenobam
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Table 1. Structure−Activity Relationship and Photoswitching Properties of the Phenylazopyridine Seriesa
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■ RESULTS AND DISCUSSION
Initial Considerations. In the eﬀort of designing
pharmacologically useful compounds for receptor activity
photoswitching, we considered three necessary conditions:
(a) biocompatible wavelengths of illumination for photo-
switching, preferably in the visible range; (b) a signiﬁcant
diﬀerence on the relative populations of the isomers between
the dark and illuminated conditions, which can be aﬀorded with
a suitable thermal relaxation of the cis isomer; and (c) a large
diﬀerence in aﬃnity/functional activity on the target protein
between the trans and cis photoisomers.
Alloswitch-1 (1a) reasonably fulﬁlled these conditions and
allowed us to control mGlu5 activity with light and to induce
light-dependent activity in behavioral experiments with living
animals, as detailed in our previous communication.11 In
contrast, SIB-1757,26 a potent phenylazopyridine mGlu5 NAM,
showed neither photoisomerization in solution nor light-
induced receptor activity switch despite the structural analogy
with alloswitch-1 in our hands (Supporting Information). This
lack of detection of photoisomerization may be due to an azo−
hydrazone tautomeric equilibrium induced by the hydroxyl of
SIB-1757, which prompts a fast thermal relaxation of its cis
isomers on the order of milliseconds29 and suggests that not all
the azobenzene ligands are well suited for controlling protein
activity with light. In addition, strong electron-donating
substituents in phenylazopyridines induce a push−pull eﬀect,
since the pyridine acts as an electron-withdrawing group, and
this leads to a further decrease of the cis isomer lifetime,30
especially in polar solvents.31 Overall, these results conﬁrmed
that the identiﬁcation of an azocompound with a suitable
pharmacological activity proﬁle is a necessary but not suﬃcient
condition to deﬁne a useful photoswitchable ligand.
Therefore, to design compounds for mGlu5 allosteric
photoregulation, we maintained the amide bond present in
alloswitch-1 for most of the compounds of the series and we
explored the structural determinants for reaching eﬀective
receptor control with light, by changing the carboxamide
substituents (Table 1). Thus, we synthesized (Supporting
Information) more bulky derivatives (1b,c) and others with
aliphatic amide substituents (1d−f), less bulky aromatic
carboxamides (1g,h), or heterocyclic rings (1i,l) (Table 1).
To investigate the eﬀect of the pyridine ring in alloswitch-1
(1a), we replaced it by a phenyl (2). We were also interested in
the eﬀects of the substitution in the central ring; therefore we
changed the position of the methoxy group (3a) or replaced it
by cyano (3b) or hydrogen (3c) substitutions.
Finally, we explored some changes on the amide group
functionality, obtaining the imides 4 or 5 or the urea 6. We also
Table 1. continued
aPIS corresponds to photoisomerization score, t1/2 corresponds to the cis isomer thermal half-life, and PPS corresponds to photoinduced potency
shift (see text).
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explored the positional isomers 7 and 8 and also synthesized
the sulfonamide 9. All these groups were expected to confer
diﬀerent electronic and structural properties to the phenyl-
azopyridine moiety, thereby altering their photoisomerization
response.
UV−Vis Absorption Spectra. We measured the UV−vis
absorption spectra of the cis and trans phenylazopyridine
isomers after chromatographic separation with HPLC-PDA-MS
(Supporting Information). The trans isomers presented typical
light absorption for the π−π* band, in the range between 310
and 400 nm, even though for most of the phenylazopyridine
compounds the maximum of this band was found around 380
nm (Figure 2A). The azobenzene cis isomers displayed a typical
n−π* band with maxima in the range 420−450 nm (Figure 2B)
The wavelength of the maximum of these bands
fundamentally depends on the nature of the substituents on
the aromatic rings of the azocompound,32 in particular electron-
donating substituents in ortho or para position.32 However, in
our cases, the 2-pyridyl group, which is a π-electron-deﬁcient
heterocycle, induces a certain push−pull character to the
azobenzene, especially in polar solvents.29 Then, to achieve a
proper π−π* band suitable for our interests, mild electron-
donating substituents are needed to shift the maximum to
longer wavelengths. An example of such is the high electron-
withdrawing sulfonamide of compound 9 shifting the band to
energetically higher wavelengths (310 nm), which are not
suitable for biological experiments. On the other hand, the urea
from compound 6, having a more electron-donating character
than the amides, shifts the band to the visible range of the
spectrum (387 nm). Moreover, we found a noticeable
correlation between this shift in the π−π* band and the
electron density of the azo moiety (Supporting Information).
Photoisomerization Studies. To measure the extent of
photoisomerization, we measured the UV−vis absorption
spectra of all compounds in the dark, after illumination with
violet light (λ = 380 nm) and after illumination with green light
(λ = 500 nm) under light conditions similar to those used in
pharmacological experiments (Figure 2C, Supporting Informa-
tion). In the dark, we practically detected only the trans isomer.
We selected 380 nm illumination (violet) to induce the trans to
cis isomerization, according to the position of the trans isomer
π−π* bands and the cis isomer π−π* and n−π* (Supporting
Information). After that, we used green light (λ = 500 nm) to
accelerate the opposite isomerization to the thermodynamically
stable trans isomer.
With the information obtained from these spectra we
calculated a “photoisomerization score” (PIS), to account for
the eﬀectiveness of the photoswitch and compare the molecules
(5, eﬃcient switching; 0, poor switching, see Supporting
Information). A large part of the compounds of the series have
photoisomerization eﬃciency similar to or better than that of
alloswitch-1 (1a) (Table 1, Figure 2D). However, in some
cases, compounds with a similar structure, such as pyridyla-
mides 1k and 1l, have a very poor photoswitching behavior,
possibly due to the fast thermal decay from the cis to the trans
isomer (Table 1, Supporting Information). Moreover, we found
a trend correlation in between the photoswitching eﬀectiveness
and the thermal relaxation rate (Supporting Information).
Additionally, the eﬃcacy of the observed photoisomerization
also depends on the selection of a suitable wavelength. For
example, some compounds such as 2 or 3c, despite having the
maximum of absorption at 366 and 358 nm respectively, display
the maximal absorbance diﬀerence between the cis and trans
isomers around 380 nm (375 and 370 nm, respectively). This
indicates that the optimal wavelength for illumination does not
necessarily correspond to that of maximum absorption, but to
the wavelength that maximizes the diﬀerence of absorption
between the trans and the cis isomers (Figure 2C). An
illustrative example is the urea 6, which has its π−π* band
maximum at 387 nm and a maximal cis−trans absorbance
diﬀerence at 395 nm. This compound has a PIS of 2 when
illuminated at 380 nm, but PIS reaches up to 5 at 400 nm
achieving a practically complete isomerization, despite the fast
relaxation of the cis isomer (t1/2 = 10 s).
In summary, we have shown that compounds like alloswitch-
1, 1f, 2, 3a, 3c, or 6 have photoisomerization properties that
make them suitable potential candidates for mGlu5 photo-
switching applications. However, other compounds like 7, 8, or
9 require harmful short UV wavelengths to achieve a proper
photoisomerization whereas some others such as 1k, 1l, or SIB-
1757 have too fast cis−trans relaxation rates that limit their
practical use in biological applications.
Pharmacological Activity on mGlu5 Receptor in Cell-
Based Assays. To study the activity of the phenylazopyr-
idines, we generated dose−response curves of the complete
series (IP accumulation assay with HEK293 expressing mGlu5
receptor) to quantitatively evaluate the antagonistic activity of
the series to quisqualate. We excluded compound 9, which was
found inactive in an initial screening (Supporting Information).
To evaluate the light-dependent eﬀects, we simultaneously
generated two curves for each compound, by incubating the
Figure 2. Spectroscopic and photosiomerization properties. (A, B)
Distribution of wavelengths of absorption in the UV−vis spectrum of
compounds in the series, detected by HPLC-PDA-MS (see Supporting
Information). Maximum of the band corresponding to (A) π−π*
transition for the trans isomers and (B) n−π* transition for the cis
isomers. (C) Example of UV−vis absorption spectra corresponding to
compound 3c, 25 μM in DMSO. The black line corresponds to the
initial spectrum in dark conditions, the violet line to the spectrum after
illumination at 380 nm, and the green line after illumination at 500
nm. Comparison of these curves with the spectra of pure trans and cis
isomers, obtained from HPLC-PDA-MS analysis (see Supporting
Information), results in a full conversion from trans to cis isomer and
near complete back-isomeration from cis to trans isomer. (D)
Distribution of photoisomerization scores (PIS) for phenylazopyr-
idines under illumination at 380 nm (violet bars) and at 500 nm
(green bars) (see text and Supporting Information).
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cells with the azocompounds in the dark and under illumination
at 380 nm (Supporting Information). As a result, we obtained
the potencies (IC50) for each compound under both
conditions. Exceptionally, compound 6 was also tested under
illumination at 400 nm.
In the dark, the phenylazopyridines displayed IC50s in the
range from low nanomolar to micromolar (Table 1 and Figure
3A). The aliphatic carboxamides 1e and 1f displayed low
nanomolar IC50 (nearly 10- and 4-fold more potent than
alloswitch-1 1a). Some other compounds were found to display
potencies comparable to that of alloswitch-1, such as 1d and
1g−k, whereas 1b, 1c, 1l, 3b, 3c, 4, 5, and 6 displayed
micromolar IC50, and some other even lower potencies (3a, 7,
and 8). Singularly, compound 2, a derivative of alloswitch-1
where the phenylazopyridine scaﬀold is replaced by an
azobenzene, only partially inhibits the response of mGlu5
(Supporting Information) despite its micromolar potency. A
plausible explanation for this diﬀerent behavior might be
attributed to a diﬀerent binding mode to the receptor, which
would prevent the full antagonistic activity found for most of
the phenylazopyridines. To investigate this point we performed
a computational docking study for compounds 2, 1e, and 1f in
an mGlu5 crystal structure.
33 The results obtained showed
diﬀerent binding modes for the azobenzene 2 compared to
phenylazopyridines 1e and 1f, which resulted to be very similar
to the docking previously reported for alloswitch-1 (1a).34
These diﬀerences in the binding modes might aﬀect mGlu5
functionality despite not aﬀecting considerably the binding
energies, which are directly related to the aﬃnity to mGlu5
receptor (Supporting Information).
In these assays, the illumination at 380 nm induced a right
shift of the dose−response curves when compared to the
nonilluminated controls, compatible with a loss of the NAM
potency of the cis isomers. Therefore, to quantify the
eﬀectiveness of the compound photoswitching, we introduced
the term “photoinduced potency shift” (PPS) as the ratio of the
IC50s under illumination and in dark conditions. We obtained a
wide variety of PPS (Table 1, Figure 2B), which are not
correlated with the potency of each compound (Supporting
Information), but have a signiﬁcant correlation with the PIS (r
= 0.77, P < 0.0001), extracted from the UV−vis absorption
spectra (Figure 2A,B). This would indicate that the functional
photoswitching of the receptor in living cells is similar to that
observed in solution for the isolated compounds (Supporting
Information).
We found very potent compounds with high PPS, such 1e
and 1f (PPS (1e) = 3.7 and PPS (1f) = 4.8), but the higher
value of PPS of compound 1f deﬁnes it as a stronger candidate
to control mGlu5 activity with light. In addition, we could ﬁnd
interesting compounds with IC50s in the micromolar range and
very high PPS, such as 1b, 3c, or 6. Speciﬁcally, compound 6
displayed large photoswitching capacities when it was
illuminated at 400 nm (PPS = 12.3), much better than those
observed at 380 nm (PPS = 4.4) (Figure 3C). Again, these
results are consistent with the wavelength dependence observed
in the trans−cis isomerization experiments of compound 6. This
eﬀect was further quantiﬁed at a single 10 μM dose of 6 in the
same cell-based assay (Figure 3D). In the dark, compound 6
induced a practically complete inhibition of mGlu5, and under
380 nm light, it still induced a 75% inhibition. However, when
400 nm light was applied, the inhibition was reduced to 25%,
compatible with the improved photoisomerization at this
wavelength, as shown above. This particular experiment
opens the possibility of inducing wavelength-dependent eﬀects
to ﬁne-control the activity of the receptor with light, which in
conventional pharmacology would require applying diﬀerent
concentrations of ligand.
Real-Time Photoswitching in Individual Cells. We next
evaluated the possible application of the observed photo-
switching to a reversible real-time control of mGlu5 receptor.
Hence, we selected the most representative phenylazopyridine
compounds and tested their eﬀects by time course of
intracellular calcium in individual HEK293 cells overexpressing
mGlu5 receptor. In the dark, all tested compounds antagonized
the calcium oscillations evoked by the activation of mGlu5 with
quisqualate, although the inhibition with 5 and 6 was not
complete, in accordance with the low potency found in IP
accumulation assays (Table 1, Supporting Information).
After a period in the dark, illumination with 380 nm light
induced the photoisomerization of the phenylazopyridines and
reestablished the calcium oscillations observed in response to
the orthosteric agonist (Figures 4AB). This eﬀect was reversed
by green illumination and could be repeated over two light
cycles for all compounds, demonstrating a reversible photo-
switch in the cellular assays as well as a real-time control of the
biological activity of mGlu5 receptor with light (Figures 4AB).
For some compounds we observed that, under 380 nm light,
the frequency of calcium oscillations was increased compared to
that observed with the orthosteric agonist alone (Figure 4B),
Figure 3. Pharmacological properties. (A) Distribution of compounds
with the IC50 values obtained with an IP accumulation assay, with
fenobam as the control. Approximately one-half of the compounds
have potencies in the nanomolar range in dark conditions, and most of
the compounds are more potent than fenobam (IC50 = 1.6 μM). (B)
Distribution of compounds with the photoinduced potency shift
(PPS) for the phenylazopyridines tested (see text). (C) IP
accumulation dose−response curve of compound 6 with 100 nM of
quisqualate in dark conditions (black), under illumination at 380 nm
(dark violet), under illumination at 400 nm (bright violet). Gray
curves correspond to the inverse agonist control (fenobam). (D)
Percentage of activation of the mGlu5 receptor with 10 μM 6 and 100
nM quisqualate. Analysis of variance (one-way ANOVA with Šidaḱ
correction for multiple comparisons; **p < 0.01, ****p < 0.0001)
showed signiﬁcant diﬀerences between dark bar and 380 nm values,
and also of 400 nm values with both dark and 380 nm values.
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suggesting an overactivation or an increased signaling of mGlu5
receptors.
After violet−green light cycles, we additionally illuminated
the cells with several wavelengths around 380 nm, to identify
the best wavelength for restoring mGlu5 activity (Figure 4AB).
The oscillatory frequencies for each illumination period were
normalized to the response to the agonist alone, plotted versus
the wavelength used for illumination, and we ﬁtted a Gaussian
curve (Figures 4CD, Supporting Information). These results
demonstrate that phenylazopyridines not only are able to
switch on and of f the mGlu5 receptor upon green and violet
illumination wavelengths but also can induce a ﬁne-tuning of its
activity. In addition, each compound of the series depends on
diﬀerent wavelengths for optimal photoswitching (peak), has
broader or sharper “functional” absorption bands (HWHM),
and presents varying degrees of receptor overactivation (Figure
5). For example, compound 1e, which was found to be the
most potent in the IP accumulation assay, is the most eﬀective
in inducing an overactivation under violet illumination (>2-fold
to agonist activation), whereas compound 3c only recovered
the response to quisqualate alone (Figure 5). The spectral
range to achieve this activation also depends on the compound.
Some have a narrow range, such as 1d or 3c, whereas others
display a wider wavelength range, as 1h, 5, or 6.
A related control of the frequency of mGlu5 calcium
oscillations was previously reported applying diﬀerent concen-
trations of a conventional NAM35 in diﬀerent cell cultures. In
contrast, the use of photoswitchable NAMs allows adjusting the
eﬀective ligand concentration by illuminating a single dose with
speciﬁc wavelengths. This suggests a way to regulate the
receptor response with a high spatiotemporal precision.
Zebraﬁsh in Vivo Screening.We ﬁnally selected the active
phenylazopyridines with a suitable eﬃcacy in IP accumulation
assays and tested on zebraﬁsh larvae behavioral assays.
The activity of all compounds was ﬁrst evaluated by
monitoring zebraﬁsh locomotion in dark conditions. Thus,
after 10 μM administration of each compound in the swimming
medium, we recorded the larva track during 30 min and the
free-swimming distance of every animal was integrated at 5 min
intervals (Figure 6B, Supporting Information). As a non-
photoswitchable control, we used 2-BisPEB, which is a potent
NAM of mGlu5
36 because fenobam, previously used in cell-
based assays, did not show signiﬁcant diﬀerences with the
vehicle. Otherwise, 2-BisPEB signiﬁcantly inhibited the zebra-
ﬁsh motility, in line with the best phenylazopyridines of this
series, such as 1a and 1f (Figure 6B).
In line with their mGlu5 NAM activities, all the tested
phenylazopyridines induced inhibition of the zebraﬁsh motility
Figure 4. Calcium imaging in individual cells illustrates the light-
dependency of mGlu5 inhibition by compounds 1f and 3c. (A, B)
Fluorescence ratio (F340/F380) over time of calcium indicator Fura-2
loaded in mGlu5-expressing HEK293 cells. Cells were challenged with
an mGlu5 agonist (ago, gray line, 3 μM quisqualate), 1 μM 3c (A) or 1
μM 1f (B) (black lines), and diﬀerent illumination wavelengths (six,
ranging between 370 and 500 nm) indicated by color boxes and
corresponding numbers above. (C, D) Quantiﬁcation of the light-
induced receptor activity in the presence of 3c (C) or 1f (D) at
indicated illumination wavelengths. Data are presented as mean ±
SEM of the normalized calcium oscillation frequency. The frequency
of calcium oscillations during an illumination period (5 min) was
calculated as number of oscillations per minute, and normalized to the
initial response to the agonist. Peak, half-width at half-maximum
(HWHM), and maximum (Max) values were inferred by ﬁtting the
data shown in the graph to a Gaussian function (magenta curve).
Figure 5. Summary of wavelength−activity relationships in single-cell
experiments. In the left graph, magenta bars indicate the illumination
wavelength (peak) at which the maximum light-induced receptor
activity is obtained for the compounds indicated. White bars represent
the range of wavelengths at which the light-induced activity is equal to
half the maximum response or more (half-width at half-maximum,
HWHM). The maximum amplitude of the light-induced receptor
activity is reported in the graph on the right, and expressed as times
the response to agonist of the naive receptors. These three parameters
(peak, HWHM, and maximum) describe the Gaussian ﬁtting
performed for all compounds on the original data from single-cell
experiments, as exempliﬁed for 1f and 3c in Figure 4C,D. Original data
were obtained from calcium imaging experiments in individual cells
(done as described in Figure 4A,B).
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25 min after their administration with diﬀerent extents, except
compounds 6 and 7, which induced a slight increase in the
animal motility (Figure 6A) when comparing to the vehicle
treated animals. In contrast, compounds 1e, 1g, and 1h, which
display nanomolar potency in IP accumulation assays, inhibited
zebraﬁsh motility with a lower eﬃcacy than expected. The
reasons for these deviations are presently unknown and can be
related to the multiple factors inﬂuencing the in vivo activity
and the characteristics of the assay. Remarkably, the magnitude
of the inhibition of the animal motility for most of the
compounds was comparable to the potencies in cell-based
assays (Supporting Information).
To evaluate the photoswitching eﬀects in vivo we performed
an extension of the assay with the same animals right after the
experiments done in dark conditions. We applied six repetitive
light cycles consisting of 1 min in dark conditions and 1 min
under violet illumination (λ = 380 nm), and the animal motility
was tracked with an integration of the free-swimming distance
every 60 s cycle. Between the violet illumination and the dark
conditions, the ﬁsh were also illuminated during 5 s with white
light to accelerate the phenylazopyridine relaxation from cis to
trans conﬁguration. Violet light prompted an increment of the
motility respective to the dark conditions for all the zebraﬁsh
tested, including vehicle and 2-BisPEB-treated ones. However,
2-BisPEB-treated animals displayed a sustained inhibition of
their motility compared to the vehicle treated animals
independently of the light conditions (Figure 6C, Supporting
Information).
As a general trend, all phenylazopyridines showed inhibitory
eﬀects in dark conditions that disappeared after shining 380 nm
light, and it was recovered in the following dark cycle, deﬁning
a fully reversible process (Supporting Information). In addition,
we found two diﬀerent behaviors under 380 nm illumination
that are dependent on the compound used: (a) a motility in
line with vehicle-treated larvae or (b) an overactivation of the
animal motility, which exceeded the levels displayed by vehicle-
treated larvae. Compounds 1a and 1f constitute a prototypical
example of these behavioral modes (Figure 6C), while in dark
conditions they equally inhibit the animal motility with a high
eﬃcacy.
This in vivo overactivation after applying violet illumination
could be related to the overactivation observed in real-time cell-
based assays and was evident for compounds 1b, 1c, 1g, and 7,
or for compounds 4, 5, and 6, as a milder eﬀect (Figure 6D,
Supporting Information). All these phenylazopyridine deriva-
tives comprise a set of compounds with very diﬀerent
potencies, from low nanomolar ranges to micromolar IC50s in
IP accumulation assays, and structurally have three aromatic
rings with a phenyl group at the amide end. In contrast, either
the group of compounds that did not prompt this over-
activation does not have this third aromatic ring or, if it is
Figure 6. In vivo screening in 7-day-old zebraﬁsh larvae. (A)
Integration of free-swimming distances in the dark during 5 and 25
min after the administration of compounds 1a−l, 2b,c and 4−7 to
aﬀord a 10 μM concentration in the medium, extracted from individual
plots (Supporting Information). Values correspond to the mean and
the SEM of the behavior of 30 animals minimum. Analysis of variance
showed statistically signiﬁcant diﬀerences of the responses of some
compounds with respect to vehicle. Values correspond to the mean
and the SEM of the behavior of 30 animals minimum. (B) In the dark,
compounds 1a and 1f decreased the motility of zebraﬁsh 30 min after
compound administration (10 μM) to an extent similar to that of 2-
BisPEB. The free-swimming distances were integrated every 5 min
during 30 min. Fenobam had a weak nonsigniﬁcant eﬀect when
compared to vehicle. Values correspond to the mean and the SEM of
the behavior of 30 animals minimum. Analysis of variance (two-way
(compound, time) ANOVA with time as repeated measure and
including the Šidaḱ correction for multiple testing; *p < 0.05, **p <
0.01, ***p < 0.001, ****p < 0.0001). (C) Eﬀect of light/dark cycles.
Compounds 1a and 1f at 10 μM inhibit animal motility similarly to 2-
bisPEB in the dark (gray background), whereas under violet light
(violet background) ﬁsh treated with 1f recover a similar behavior to
vehicle treated controls (blue line). Zebraﬁsh larvae treated with 1a
experience an increase of their normal motility under violet light (red
line). In the ﬁgure we show the light/dark cycles from 4 to 12 min.
Values correspond to the mean and the SEM of the behavior of 24
animals minimum. (D) In vivo photoswitching eﬃcacy of compounds
1a−l, 2b,c, and 4−7 with the corresponding variance analysis. Each bar
corresponds to the mean of the sum of the free swimming distances in
all the dark or violet illuminated points for each experiment (4
experiments with 6 animals per experiment) subtracting the
corresponding sum of distances of the 2-BisPEB-treated animals and
Figure 6. continued
normalizing the distances by the lower distance mean of the set (0%)
and the mean corresponding to the vehicle-treated animals (100%).
The subtraction of the 2-BisPEB eﬀect was done to minimize the eﬀect
of the light not corresponding to the eﬀect of the administered
compounds. The error bars correspond to the associated SEM.
Analysis of variance (two-way (compound, light conditions) ANOVA
with light conditions as a repeated measure and including the Šidaḱ
correction for multiple comparisons; *p < 0.05, **p < 0.01, ***p <
0.001, ****p < 0.0001).
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present, its electron density is low due to the presence of
electron-withdrawing groups, like ﬂuorine, or they have
pyridines, which are intrinsically electron poor. Compound 7
constitutes a particular case, since it also induces overactivation
under illumination and includes a 2-pyridylcarboxamide ring as
the third aromatic ring. However, it is the only compound
tested with 1,3 substitution in the central ring, which is
expected to induce a lower inﬂuence on the π electron density
of the azo bond. Intriguingly, not all the compounds that
induce this overactivation do it in real-time cell assays. For
example, compounds 1e, 1f, and 1i, with a higher overactivation
eﬀect in cell-based assays, did not induce a measurable
overactivation in animal motility. In contrast, 1b, unable to
produce the receptor overactivations in cell-based assays,
induced the highest overactivation in vivo. This may be due
to diﬀerences in these two assays, which use diﬀerent
illumination protocols and test mammalian and zebraﬁsh
mGlu5 receptors respectively, whose functionalities can diﬀer
considerably. In any case, this atypical eﬀect appears to be light
dependent, could only be detected with photoswitchable
compounds, and will be subject of future studies.
Regarding the in vivo photoswitchable properties of the
phenylazopyridines, all of them induce photoswitching in
zebraﬁsh motility (Figure 6D) to diﬀerent extents. The
compounds that promoted an overactivation of the animal
motility under violet light show higher statistical signiﬁcances in
their photoswitching. Even so, diﬀerences for the rest of
compounds were still signiﬁcant, except for compound 1d,
whose in vivo activity was abnormally weak, and 1k and 1l,
which also performed poorly in cell assays (PPS(1k) = 1.3,
PPS(1l) = 1.2), probably as a consequence of their limited
intrinsic low photoisomerization capacity (PIS380(1k) = 1,
PIS500(1k) = 1; PIS380(1l) = 1 PIS500(1l) = 0). In fact, if
compound 1d and the compounds with overactivation behavior
are not taken into account, the diﬀerence between the violet
and dark values of each compound in Figure 6D correlates with
photoisomerization score (PIS) (r = 0.70, P = 0.025) and with
photoinduced potency shift (PPS) logarithm (r = 0.83, P =
0.0031) (Supporting Information), showing a remarkable
consistency of the photoisomerization throughout the diﬀerent
assays, from compound in solution to cell-based in vitro assays
and in vivo behavioral experiments.
Rodent in Vivo Pain Assay. Next, we aimed to assess
photoswitching in rodent tissue. We used a classical animal
model of pain based on the intraplantar administration of
formalin (Supporting Information) since local plantar blockade
of group I mGluRs was reported to reduce the spontaneous
formalin behavior.37 Thus, we monitored the local eﬃcacy of
compounds 1e and 1f to modify the formalin-mediated
nociception in dark and upon illumination with violet light
(Figure 7A). As expected, both compounds showed anti-
nociceptive properties in dark conditions since the mouse
licking paw time was signiﬁcantly reduced when compared to
the vehicle condition (Figure 7A).
Interestingly, compounds 1f and 1e were equipotent or even
more eﬀective, respectively, when compared to the mGlu5
NAM reference compound used (raseglurant, Chart 1, Figure
7A). Importantly, the intrinsic antinociceptive eﬃcacy of both
compounds was signiﬁcantly reduced upon external paw
illumination with violet light, thus suggesting that local
photoisomerization was achieved while monitoring nociception
(Figure 7A).
We next examined the in vivo phenylazopyridine photo-
switching in mouse CNS, since mGlu5 receptor is expressed in
amygdala and its activation is related to pain-like eﬀects.38 We
evaluated the mechanical allodynia in a CFA-induced persistent
inﬂammatory pain model by using the von Frey technique
(Supporting Information). Mice were stereotaxically implanted
with hybrid optic and ﬂuid cannulas in the amygdala allowing
the controlled administration of compounds and light in freely
behaving animals. Amygdala injection of alloswitch-1 (1a)
restored the mechanical sensitivity to the level of naive mice
(before inﬂammation), compatible with the trans active form of
the compound (Figure 7B). The observed analgesic eﬀect was
abolished after amygdala illumination at 385 nm (Figure 7B).
That suggests that the local photoisomerization of 1a from
trans to cis conﬁguration in the amygdala can control the
analgesic eﬀect of the compound in peripheral tissues. In
Figure 7. Photoswitching of pain-like behavior in mice. (A) Local
photoswitching in the mouse hindpaw. The mouse hindpaw was
injected with vehicle (20% DMSO + 20% Tween-80 in saline), 5 mM
raseglurant (Rasegl.), 5 mM compound 1e or 5 mM compound 1f and
then illumination at 405 nm (or dark) during 15 min was performed
(n = 6 for each condition). Subsequently, the total hindpaw licking (in
seconds) was measured during 5 min after the intraplantar injection of
formalin solution (2.5% paraformaldehyde). The scheme of the
protocol used is depicted in the upper inset. Analysis of variance (one-
way ANOVA with Šidaḱ correction for multiple comparisons; **p <
0.01, ***p < 0.001) showed signiﬁcant diﬀerences between dark and
405 nm values for phenylazopyridines 1e and 1f, but not for vehicle
and raseglurant. (B) Local photoswitching in mouse amygdala.
Persistent inﬂammatory pain was induced by unilateral intraplantar
injection of 30 μL of complete Freund’s adjuvant (CFA) in the left
hind paw. Mechanical allodynia was measured by stimulating the CFA-
treated hindpaw with a 1.4 g von Frey ﬁlament after intra-amygdala
injection of vehicle (0.003% DMSO in PBS, n = 11) or compound 1a
(300 nM, n = 13) in dark condition and with amygdala illumination at
385 nm. Naive-mouse mechanical sensitivity was measured before
CFA injection (n = 11). The scheme of the protocol used is also
depicted in the upper inset. Analysis of variance (one-way ANOVA
with Šidaḱ correction for multiple comparisons; ****p < 0.0001)
showed signiﬁcant diﬀerences between dark and 385 nm values for 1a
but not for vehicle and showed nonsigniﬁcant diﬀerences between the
naive mice and those treated with 1a with no illumination.
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contrast, 385 nm illumination induced no eﬀect with vehicle
conditions (Figure 7B).
These results conﬁrm that phenylazopyridines can be used
for local control of mGlu5 with light in behaving rodents, both
peripherally and in the CNS, opening uses of photo-
pharmacology in disease models and behavioral assays.
■ CONCLUDING REMARKS
We synthesized a series of photoswitchable mGlu5 NAMs based
on the phenylazopyridine scaﬀold, with a robust SAR, since
almost all the trans isomers were active on mGlu5 and half of
them signiﬁcantly inhibited zebraﬁsh motility at 10 μM
concentration. We obtained compounds with diﬀerent photo-
isomerization properties, and their translation to in vitro and in
vivo assays was also robust, since very few compounds lost their
photoswitching properties in any of the diﬀerent subsequent
assays in spite of the increasing complexity of the biological
tests. From these compounds, we obtained excellent photo-
switching behavior in all the assays performed with compounds
1a, 1f, 1i, 1j, and 3c as well as 6, in which we aﬀorded a more
powerful eﬀect at more cell-compatible blue-shifted wave-
lengths. To account for the eﬃciency in the photoswitching we
have proposed two parameters: the photoisomerization score
(PIS) and the photoinduced potency shift (PPS).
Additionally, these phenylazopyridines allowed us to deﬁne a
way to perform a ﬁne control of mGlu5 receptor activity by
tuning the wavelength of illumination between 360 and 500
nm, and, depending on the compound used, we were able to
control an overactivation of the receptor. This functional
overactivation was also detected in vivo after treating zebraﬁsh
larvae with some speciﬁc compounds, but not with others. The
reasons for this light-dependent atypical eﬀect could be linked
to the potentiation of calcium responses in single cell assays
and require further investigation. Finally, mGlu5 NAM
phenylazopyridines showed analgesic eﬀects in rodents, which
can be regulated by peripheral violet illumination or directly in
the CNS, thus validating the potential usefulness of allosteric
mGlu5 photopharmacology in vivo. Overall, photoswitchable
phenylazopyridines reveal new paradigms on the ligand-
induced protein responses with potential to add a new
modulatory dimension to drug therapeutics.
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